| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 14 | 2025 | 341 | 2.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 10 | 2015 | 263 | 2.090 |
Why?
|
| Diet | 17 | 2025 | 460 | 1.950 |
Why?
|
| Rheumatic Heart Disease | 9 | 2025 | 32 | 1.810 |
Why?
|
| Heart Defects, Congenital | 12 | 2025 | 380 | 1.640 |
Why?
|
| Feeding Behavior | 7 | 2016 | 338 | 1.530 |
Why?
|
| Child | 62 | 2025 | 7618 | 1.430 |
Why?
|
| Microbiota | 8 | 2023 | 426 | 1.410 |
Why?
|
| Infant | 33 | 2025 | 3360 | 1.140 |
Why?
|
| Colorectal Neoplasms | 6 | 2022 | 1069 | 1.130 |
Why?
|
| Adolescent | 53 | 2025 | 9873 | 1.110 |
Why?
|
| Female | 106 | 2025 | 49869 | 1.030 |
Why?
|
| Child, Preschool | 32 | 2025 | 3970 | 1.030 |
Why?
|
| Humans | 136 | 2025 | 95799 | 0.930 |
Why?
|
| Male | 92 | 2025 | 45685 | 0.920 |
Why?
|
| Mothers | 3 | 2021 | 155 | 0.850 |
Why?
|
| Vegetables | 3 | 2013 | 50 | 0.850 |
Why?
|
| Cardiac Surgical Procedures | 6 | 2025 | 514 | 0.840 |
Why?
|
| Fruit | 3 | 2013 | 81 | 0.840 |
Why?
|
| Postmenopause | 4 | 2013 | 107 | 0.830 |
Why?
|
| Retrospective Studies | 44 | 2025 | 10273 | 0.810 |
Why?
|
| Cohort Studies | 24 | 2025 | 3106 | 0.790 |
Why?
|
| Risk Factors | 30 | 2025 | 5961 | 0.790 |
Why?
|
| Virtual Reality | 5 | 2023 | 39 | 0.790 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2023 | 162 | 0.790 |
Why?
|
| Young Adult | 35 | 2025 | 7026 | 0.780 |
Why?
|
| Nutritional Status | 2 | 2014 | 82 | 0.780 |
Why?
|
| Lung Transplantation | 5 | 2025 | 367 | 0.770 |
Why?
|
| Infant, Newborn | 22 | 2025 | 2610 | 0.730 |
Why?
|
| Case-Control Studies | 17 | 2025 | 1957 | 0.690 |
Why?
|
| Health Behavior | 3 | 2011 | 191 | 0.670 |
Why?
|
| C-Reactive Protein | 3 | 2025 | 206 | 0.670 |
Why?
|
| Lipocalin-2 | 3 | 2025 | 39 | 0.670 |
Why?
|
| Heart Ventricles | 6 | 2025 | 810 | 0.660 |
Why?
|
| Weight Perception | 1 | 2020 | 1 | 0.650 |
Why?
|
| Mother-Child Relations | 1 | 2020 | 31 | 0.640 |
Why?
|
| Body Image | 1 | 2020 | 84 | 0.620 |
Why?
|
| Crohn Disease | 5 | 2025 | 809 | 0.600 |
Why?
|
| Registries | 7 | 2025 | 985 | 0.590 |
Why?
|
| Pediatrics | 7 | 2021 | 399 | 0.570 |
Why?
|
| Cerebrovascular Circulation | 1 | 2020 | 243 | 0.570 |
Why?
|
| Prospective Studies | 22 | 2025 | 4664 | 0.560 |
Why?
|
| Adult | 42 | 2025 | 28578 | 0.550 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2025 | 172 | 0.550 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2025 | 590 | 0.520 |
Why?
|
| Fontan Procedure | 3 | 2023 | 56 | 0.510 |
Why?
|
| Surveys and Questionnaires | 9 | 2020 | 2859 | 0.480 |
Why?
|
| Urine | 1 | 2016 | 96 | 0.480 |
Why?
|
| Aged | 31 | 2025 | 20848 | 0.480 |
Why?
|
| Body Mass Index | 9 | 2025 | 815 | 0.470 |
Why?
|
| Meat Products | 2 | 2012 | 7 | 0.470 |
Why?
|
| Milk, Human | 3 | 2025 | 51 | 0.460 |
Why?
|
| Food | 2 | 2015 | 93 | 0.450 |
Why?
|
| Soy Foods | 2 | 2011 | 3 | 0.450 |
Why?
|
| Ileum | 3 | 2025 | 169 | 0.450 |
Why?
|
| Calcium, Dietary | 1 | 2015 | 68 | 0.440 |
Why?
|
| Middle Aged | 33 | 2025 | 28206 | 0.440 |
Why?
|
| Rheumatic Fever | 3 | 2024 | 12 | 0.440 |
Why?
|
| Premature Birth | 1 | 2016 | 130 | 0.440 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2025 | 84 | 0.430 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2014 | 3 | 0.430 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2014 | 12 | 0.430 |
Why?
|
| Renal Replacement Therapy | 5 | 2025 | 43 | 0.430 |
Why?
|
| Curriculum | 7 | 2023 | 615 | 0.420 |
Why?
|
| Pancreatitis | 2 | 2025 | 94 | 0.410 |
Why?
|
| Proportional Hazards Models | 11 | 2023 | 900 | 0.400 |
Why?
|
| Leptin | 2 | 2014 | 102 | 0.400 |
Why?
|
| Muscular Dystrophy, Duchenne | 2 | 2024 | 39 | 0.400 |
Why?
|
| Energy Intake | 5 | 2017 | 100 | 0.400 |
Why?
|
| Metagenomics | 2 | 2025 | 100 | 0.390 |
Why?
|
| Carotenoids | 2 | 2013 | 17 | 0.390 |
Why?
|
| Adiponectin | 1 | 2013 | 21 | 0.390 |
Why?
|
| Risk Assessment | 10 | 2025 | 2480 | 0.390 |
Why?
|
| Diet, Western | 1 | 2013 | 45 | 0.380 |
Why?
|
| Phytanic Acid | 1 | 2012 | 3 | 0.380 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2023 | 46 | 0.380 |
Why?
|
| Renal Dialysis | 3 | 2025 | 364 | 0.380 |
Why?
|
| Hawaii | 10 | 2016 | 26 | 0.380 |
Why?
|
| Smoking | 3 | 2013 | 649 | 0.380 |
Why?
|
| Secondary Prevention | 2 | 2025 | 179 | 0.370 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2025 | 110 | 0.370 |
Why?
|
| Heterocyclic Compounds | 1 | 2012 | 19 | 0.370 |
Why?
|
| Food Supply | 1 | 2012 | 31 | 0.370 |
Why?
|
| Amines | 1 | 2012 | 31 | 0.370 |
Why?
|
| Somatomedins | 1 | 2012 | 28 | 0.370 |
Why?
|
| Atrial Function, Left | 2 | 2023 | 54 | 0.360 |
Why?
|
| Phytoestrogens | 1 | 2011 | 2 | 0.360 |
Why?
|
| Uganda | 7 | 2025 | 46 | 0.360 |
Why?
|
| Heart | 4 | 2023 | 590 | 0.360 |
Why?
|
| Isoflavones | 1 | 2011 | 13 | 0.360 |
Why?
|
| Growth Inhibitors | 1 | 2011 | 41 | 0.360 |
Why?
|
| Fabaceae | 1 | 2011 | 25 | 0.360 |
Why?
|
| Norwood Procedures | 2 | 2024 | 40 | 0.350 |
Why?
|
| Cardiac Volume | 2 | 2022 | 53 | 0.350 |
Why?
|
| Heart Transplantation | 3 | 2022 | 811 | 0.340 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2025 | 217 | 0.340 |
Why?
|
| Treatment Outcome | 17 | 2025 | 9167 | 0.330 |
Why?
|
| Food Labeling | 1 | 2010 | 8 | 0.330 |
Why?
|
| Aortic Diseases | 2 | 2023 | 104 | 0.330 |
Why?
|
| United States | 15 | 2025 | 7764 | 0.330 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 569 | 0.320 |
Why?
|
| Postoperative Complications | 4 | 2025 | 2592 | 0.320 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2025 | 3639 | 0.320 |
Why?
|
| Heart Rate | 2 | 2025 | 518 | 0.320 |
Why?
|
| Blood Glucose | 2 | 2025 | 873 | 0.310 |
Why?
|
| Hypertension, Pulmonary | 2 | 2024 | 381 | 0.310 |
Why?
|
| Communication | 3 | 2018 | 478 | 0.310 |
Why?
|
| Papillomavirus Vaccines | 2 | 2022 | 59 | 0.300 |
Why?
|
| Social Determinants of Health | 3 | 2021 | 111 | 0.300 |
Why?
|
| Follow-Up Studies | 10 | 2025 | 3904 | 0.300 |
Why?
|
| Health Status Disparities | 2 | 2014 | 221 | 0.300 |
Why?
|
| Biomarkers | 7 | 2025 | 1931 | 0.300 |
Why?
|
| Predictive Value of Tests | 9 | 2025 | 1805 | 0.290 |
Why?
|
| Body Weight | 3 | 2023 | 460 | 0.290 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2023 | 340 | 0.290 |
Why?
|
| Endometrial Neoplasms | 1 | 2011 | 228 | 0.290 |
Why?
|
| Hemodynamics | 2 | 2023 | 775 | 0.270 |
Why?
|
| Nutrition Surveys | 3 | 2014 | 125 | 0.270 |
Why?
|
| Reproducibility of Results | 7 | 2025 | 2882 | 0.270 |
Why?
|
| Papillomavirus Infections | 3 | 2022 | 301 | 0.270 |
Why?
|
| California | 6 | 2016 | 161 | 0.270 |
Why?
|
| Internship and Residency | 6 | 2023 | 1134 | 0.270 |
Why?
|
| RNA, Ribosomal, 16S | 5 | 2023 | 259 | 0.270 |
Why?
|
| Primary Health Care | 4 | 2025 | 391 | 0.270 |
Why?
|
| Infant Care | 2 | 2017 | 7 | 0.260 |
Why?
|
| Vaccination Refusal | 2 | 2017 | 10 | 0.260 |
Why?
|
| Dysbiosis | 2 | 2025 | 91 | 0.260 |
Why?
|
| Child Development | 2 | 2021 | 174 | 0.260 |
Why?
|
| Diet Records | 3 | 2017 | 20 | 0.260 |
Why?
|
| Metagenome | 3 | 2022 | 116 | 0.250 |
Why?
|
| Insulin | 1 | 2012 | 1190 | 0.250 |
Why?
|
| Obesity | 4 | 2015 | 1030 | 0.250 |
Why?
|
| Waiting Lists | 2 | 2025 | 212 | 0.250 |
Why?
|
| Nutrition Assessment | 4 | 2016 | 21 | 0.240 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2023 | 647 | 0.240 |
Why?
|
| Age Factors | 6 | 2025 | 1957 | 0.240 |
Why?
|
| Education, Medical, Graduate | 3 | 2019 | 436 | 0.240 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2020 | 630 | 0.240 |
Why?
|
| Penicillin G Benzathine | 1 | 2025 | 6 | 0.230 |
Why?
|
| Atrial Function, Right | 1 | 2025 | 14 | 0.230 |
Why?
|
| Colitis, Ulcerative | 2 | 2023 | 801 | 0.230 |
Why?
|
| Exercise Tolerance | 2 | 2023 | 66 | 0.230 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2025 | 4 | 0.230 |
Why?
|
| Citric Acid | 1 | 2025 | 48 | 0.230 |
Why?
|
| Arterial Pressure | 1 | 2025 | 42 | 0.230 |
Why?
|
| Cross-Sectional Studies | 5 | 2016 | 1878 | 0.230 |
Why?
|
| Accessory Atrioventricular Bundle | 1 | 2025 | 2 | 0.230 |
Why?
|
| Pilot Projects | 6 | 2025 | 936 | 0.220 |
Why?
|
| Coronary Sinus | 1 | 2025 | 10 | 0.220 |
Why?
|
| Pregnancy | 7 | 2023 | 3237 | 0.220 |
Why?
|
| Heart Injuries | 1 | 2025 | 22 | 0.220 |
Why?
|
| Chemokines, CC | 1 | 2024 | 37 | 0.220 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 593 | 0.220 |
Why?
|
| Breast Neoplasms | 3 | 2013 | 3155 | 0.220 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2024 | 5 | 0.220 |
Why?
|
| Severity of Illness Index | 7 | 2025 | 1981 | 0.220 |
Why?
|
| Logistic Models | 5 | 2024 | 1267 | 0.220 |
Why?
|
| Hospitalization | 2 | 2021 | 943 | 0.220 |
Why?
|
| Vasopressins | 1 | 2024 | 50 | 0.220 |
Why?
|
| Heart Atria | 2 | 2023 | 290 | 0.220 |
Why?
|
| Cryosurgery | 1 | 2025 | 65 | 0.210 |
Why?
|
| Renal Insufficiency | 1 | 2025 | 99 | 0.210 |
Why?
|
| Furosemide | 1 | 2024 | 33 | 0.210 |
Why?
|
| Dermatitis, Atopic | 1 | 2025 | 66 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2025 | 2773 | 0.210 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2024 | 46 | 0.210 |
Why?
|
| Ventricular Premature Complexes | 1 | 2024 | 8 | 0.210 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2024 | 47 | 0.210 |
Why?
|
| Vasoconstrictor Agents | 1 | 2024 | 68 | 0.210 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 77 | 0.210 |
Why?
|
| Thrombocytopenia | 1 | 2025 | 187 | 0.210 |
Why?
|
| Cation Transport Proteins | 1 | 2024 | 70 | 0.210 |
Why?
|
| Electrocardiography | 3 | 2025 | 522 | 0.210 |
Why?
|
| Hyperglycemia | 1 | 2025 | 181 | 0.210 |
Why?
|
| Fatty Acids | 2 | 2016 | 152 | 0.210 |
Why?
|
| Influenza, Human | 2 | 2017 | 370 | 0.200 |
Why?
|
| Creatinine | 1 | 2024 | 299 | 0.200 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2024 | 58 | 0.200 |
Why?
|
| Neutrophils | 1 | 2025 | 328 | 0.200 |
Why?
|
| Cognition | 2 | 2020 | 635 | 0.200 |
Why?
|
| Ambulatory Care | 1 | 2025 | 198 | 0.200 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2024 | 107 | 0.200 |
Why?
|
| Myocarditis | 1 | 2024 | 58 | 0.200 |
Why?
|
| Isosorbide Dinitrate | 1 | 2023 | 2 | 0.200 |
Why?
|
| Pulmonary Artery | 1 | 2025 | 340 | 0.200 |
Why?
|
| Arterial Switch Operation | 1 | 2023 | 5 | 0.200 |
Why?
|
| Guideline Adherence | 1 | 2025 | 245 | 0.200 |
Why?
|
| Transposition of Great Vessels | 1 | 2023 | 24 | 0.190 |
Why?
|
| Lymphocytes | 1 | 2025 | 465 | 0.190 |
Why?
|
| Echocardiography | 4 | 2023 | 1004 | 0.190 |
Why?
|
| Incidence | 5 | 2021 | 1714 | 0.190 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2013 | 43 | 0.190 |
Why?
|
| Multiple Organ Failure | 1 | 2023 | 60 | 0.190 |
Why?
|
| Phenotype | 3 | 2024 | 2575 | 0.190 |
Why?
|
| Fusobacterium nucleatum | 1 | 2022 | 6 | 0.190 |
Why?
|
| Patient Compliance | 2 | 2017 | 239 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 2 | 2025 | 847 | 0.190 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2023 | 116 | 0.190 |
Why?
|
| Ohio | 5 | 2021 | 42 | 0.190 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1176 | 0.190 |
Why?
|
| Catheter Ablation | 1 | 2025 | 266 | 0.180 |
Why?
|
| Staphylococcal Infections | 1 | 2025 | 289 | 0.180 |
Why?
|
| Infant, Premature | 1 | 2024 | 308 | 0.180 |
Why?
|
| Staphylococcus aureus | 1 | 2025 | 285 | 0.180 |
Why?
|
| Survivors | 2 | 2015 | 204 | 0.180 |
Why?
|
| Linear Models | 2 | 2014 | 438 | 0.180 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 45 | 0.180 |
Why?
|
| Anticoagulants | 1 | 2025 | 463 | 0.180 |
Why?
|
| Biliary Atresia | 1 | 2022 | 24 | 0.180 |
Why?
|
| Cohort Effect | 1 | 2021 | 7 | 0.180 |
Why?
|
| Streptococcal Infections | 1 | 2022 | 57 | 0.180 |
Why?
|
| Poverty | 2 | 2021 | 196 | 0.180 |
Why?
|
| Adult Children | 1 | 2021 | 14 | 0.180 |
Why?
|
| Diabetes Mellitus | 2 | 2021 | 771 | 0.180 |
Why?
|
| Cholestasis | 1 | 2022 | 44 | 0.180 |
Why?
|
| Skin | 1 | 2025 | 604 | 0.180 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2021 | 27 | 0.180 |
Why?
|
| Hospital Mortality | 1 | 2024 | 483 | 0.180 |
Why?
|
| Bacterial Load | 1 | 2021 | 20 | 0.180 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2023 | 143 | 0.180 |
Why?
|
| Syncope | 1 | 2021 | 37 | 0.170 |
Why?
|
| Analysis of Variance | 2 | 2014 | 908 | 0.170 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 47 | 0.170 |
Why?
|
| Liver | 2 | 2023 | 1231 | 0.170 |
Why?
|
| Mental Recall | 2 | 2015 | 173 | 0.170 |
Why?
|
| Feces | 4 | 2025 | 360 | 0.170 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2023 | 167 | 0.170 |
Why?
|
| Mycobiome | 1 | 2020 | 1 | 0.170 |
Why?
|
| Tetralogy of Fallot | 1 | 2021 | 45 | 0.170 |
Why?
|
| Decision Making | 2 | 2020 | 694 | 0.170 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2020 | 13 | 0.170 |
Why?
|
| Erythropoiesis | 1 | 2021 | 53 | 0.170 |
Why?
|
| Thrombophilia | 1 | 2020 | 23 | 0.170 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 32 | 0.170 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 56 | 0.160 |
Why?
|
| Tissue Donors | 2 | 2022 | 542 | 0.160 |
Why?
|
| Risk Adjustment | 1 | 2020 | 40 | 0.160 |
Why?
|
| Atrial Function | 1 | 2020 | 19 | 0.160 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2023 | 209 | 0.160 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2021 | 61 | 0.160 |
Why?
|
| Electric Countershock | 1 | 2021 | 64 | 0.160 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 72 | 0.160 |
Why?
|
| Stroke Volume | 4 | 2025 | 531 | 0.160 |
Why?
|
| Blood Gas Analysis | 1 | 2020 | 38 | 0.160 |
Why?
|
| Carcinogenesis | 1 | 2022 | 235 | 0.160 |
Why?
|
| Cardiology | 1 | 2021 | 130 | 0.160 |
Why?
|
| Time Factors | 6 | 2025 | 5561 | 0.160 |
Why?
|
| Primary Prevention | 1 | 2021 | 86 | 0.160 |
Why?
|
| Electrodes, Implanted | 1 | 2021 | 219 | 0.160 |
Why?
|
| Bacteria | 2 | 2021 | 517 | 0.160 |
Why?
|
| Life Style | 2 | 2011 | 186 | 0.160 |
Why?
|
| Environmental Monitoring | 1 | 2020 | 89 | 0.160 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2020 | 111 | 0.160 |
Why?
|
| Sepsis | 1 | 2024 | 389 | 0.160 |
Why?
|
| Delirium | 1 | 2021 | 79 | 0.160 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2020 | 52 | 0.160 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 206 | 0.160 |
Why?
|
| Air Pollution | 1 | 2021 | 107 | 0.160 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 43 | 0.150 |
Why?
|
| Tachycardia, Ventricular | 1 | 2021 | 132 | 0.150 |
Why?
|
| Air Pollution, Indoor | 1 | 2020 | 80 | 0.150 |
Why?
|
| Intestinal Mucosa | 1 | 2024 | 825 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2025 | 647 | 0.150 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2019 | 21 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2020 | 157 | 0.150 |
Why?
|
| Carbon Dioxide | 1 | 2020 | 212 | 0.150 |
Why?
|
| Patient Simulation | 1 | 2019 | 51 | 0.150 |
Why?
|
| Wound Healing | 1 | 2021 | 378 | 0.150 |
Why?
|
| Motor Activity | 2 | 2012 | 332 | 0.150 |
Why?
|
| Defibrillators, Implantable | 1 | 2021 | 156 | 0.150 |
Why?
|
| Colectomy | 1 | 2020 | 192 | 0.150 |
Why?
|
| Prognosis | 4 | 2025 | 3990 | 0.150 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2020 | 106 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2020 | 294 | 0.140 |
Why?
|
| Self Report | 2 | 2017 | 328 | 0.140 |
Why?
|
| Influenza Vaccines | 2 | 2017 | 173 | 0.140 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 240 | 0.140 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 7215 | 0.140 |
Why?
|
| Formative Feedback | 1 | 2018 | 15 | 0.140 |
Why?
|
| Environmental Exposure | 1 | 2021 | 356 | 0.140 |
Why?
|
| Parents | 2 | 2018 | 307 | 0.140 |
Why?
|
| Family | 1 | 2020 | 331 | 0.140 |
Why?
|
| Survival Rate | 4 | 2024 | 1971 | 0.140 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 58 | 0.140 |
Why?
|
| Aorta | 1 | 2019 | 294 | 0.140 |
Why?
|
| Professional Competence | 1 | 2018 | 72 | 0.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 187 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1096 | 0.140 |
Why?
|
| Thrombosis | 1 | 2020 | 326 | 0.130 |
Why?
|
| Calcinosis | 1 | 2019 | 232 | 0.130 |
Why?
|
| Vaccination Coverage | 1 | 2017 | 7 | 0.130 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 255 | 0.130 |
Why?
|
| Coronary Vessels | 1 | 2019 | 201 | 0.130 |
Why?
|
| Socioeconomic Factors | 3 | 2021 | 640 | 0.130 |
Why?
|
| Gene Expression | 1 | 2021 | 1319 | 0.130 |
Why?
|
| Books | 1 | 2017 | 4 | 0.130 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 166 | 0.130 |
Why?
|
| Pamphlets | 1 | 2017 | 14 | 0.130 |
Why?
|
| Learning | 2 | 2019 | 305 | 0.130 |
Why?
|
| Asthma | 2 | 2025 | 1051 | 0.130 |
Why?
|
| Quality Improvement | 2 | 2021 | 502 | 0.130 |
Why?
|
| Aortic Valve | 1 | 2019 | 273 | 0.130 |
Why?
|
| Preventive Health Services | 1 | 2017 | 39 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2019 | 276 | 0.130 |
Why?
|
| Sudden Infant Death | 1 | 2017 | 34 | 0.130 |
Why?
|
| Office Visits | 1 | 2017 | 52 | 0.130 |
Why?
|
| Risk | 3 | 2017 | 665 | 0.130 |
Why?
|
| Child Health Services | 1 | 2017 | 51 | 0.130 |
Why?
|
| Meat | 2 | 2016 | 27 | 0.130 |
Why?
|
| Lactation | 1 | 2016 | 55 | 0.120 |
Why?
|
| Diet, Mediterranean | 1 | 2016 | 6 | 0.120 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 94 | 0.120 |
Why?
|
| Dietary Fats | 3 | 2013 | 137 | 0.120 |
Why?
|
| Patient Discharge | 1 | 2019 | 361 | 0.120 |
Why?
|
| Trisaccharides | 1 | 2015 | 12 | 0.120 |
Why?
|
| Interviews as Topic | 1 | 2017 | 376 | 0.120 |
Why?
|
| Cervix Uteri | 1 | 2016 | 73 | 0.120 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2016 | 35 | 0.120 |
Why?
|
| Physicians | 1 | 2023 | 706 | 0.120 |
Why?
|
| Health Promotion | 1 | 2017 | 176 | 0.120 |
Why?
|
| Short Bowel Syndrome | 1 | 2015 | 38 | 0.120 |
Why?
|
| Shellfish | 1 | 2015 | 5 | 0.120 |
Why?
|
| Seafood | 1 | 2015 | 11 | 0.120 |
Why?
|
| Mortality | 1 | 2016 | 154 | 0.110 |
Why?
|
| Neoplasms | 1 | 2011 | 3242 | 0.110 |
Why?
|
| Internet | 1 | 2017 | 340 | 0.110 |
Why?
|
| Overweight | 1 | 2015 | 121 | 0.110 |
Why?
|
| SEER Program | 2 | 2013 | 235 | 0.110 |
Why?
|
| Dietary Fiber | 2 | 2013 | 46 | 0.110 |
Why?
|
| Adipokines | 1 | 2014 | 18 | 0.110 |
Why?
|
| Tocopherols | 1 | 2013 | 6 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 80 | 0.100 |
Why?
|
| Diet Surveys | 1 | 2013 | 21 | 0.100 |
Why?
|
| Bone Density | 1 | 2015 | 239 | 0.100 |
Why?
|
| Survival Analysis | 2 | 2014 | 1540 | 0.100 |
Why?
|
| Hypertension | 1 | 2019 | 774 | 0.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 74 | 0.100 |
Why?
|
| Factor Analysis, Statistical | 1 | 2013 | 118 | 0.100 |
Why?
|
| Adaptation, Physiological | 1 | 2015 | 340 | 0.100 |
Why?
|
| Nebraska | 1 | 2012 | 14 | 0.100 |
Why?
|
| Matrix Metalloproteinases | 1 | 2012 | 30 | 0.100 |
Why?
|
| Vitamin B 6 | 1 | 2012 | 3 | 0.100 |
Why?
|
| Intestines | 1 | 2015 | 432 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 318 | 0.090 |
Why?
|
| Mutation | 1 | 2024 | 4374 | 0.090 |
Why?
|
| Erythrocyte Membrane | 1 | 2012 | 61 | 0.090 |
Why?
|
| Acute Disease | 2 | 2025 | 859 | 0.090 |
Why?
|
| Critical Illness | 2 | 2025 | 346 | 0.090 |
Why?
|
| Environment Design | 1 | 2012 | 9 | 0.090 |
Why?
|
| Exercise | 4 | 2021 | 355 | 0.090 |
Why?
|
| Cause of Death | 1 | 2013 | 278 | 0.090 |
Why?
|
| Genistein | 1 | 2011 | 16 | 0.090 |
Why?
|
| Lipoproteins, HDL | 2 | 2023 | 93 | 0.090 |
Why?
|
| Abdominal Pain | 2 | 2023 | 145 | 0.090 |
Why?
|
| Nipple Aspirate Fluid | 1 | 2011 | 1 | 0.090 |
Why?
|
| Soybean Proteins | 1 | 2011 | 5 | 0.090 |
Why?
|
| Estrone | 1 | 2011 | 10 | 0.090 |
Why?
|
| Geography | 1 | 2012 | 240 | 0.090 |
Why?
|
| Respiration, Artificial | 2 | 2025 | 423 | 0.090 |
Why?
|
| Exercise Test | 2 | 2023 | 178 | 0.090 |
Why?
|
| Length of Stay | 2 | 2025 | 833 | 0.090 |
Why?
|
| Gestational Age | 2 | 2023 | 343 | 0.080 |
Why?
|
| Cataract | 1 | 2011 | 87 | 0.080 |
Why?
|
| Organ Size | 2 | 2022 | 376 | 0.080 |
Why?
|
| Dietary Sucrose | 1 | 2010 | 14 | 0.080 |
Why?
|
| Estradiol | 1 | 2011 | 255 | 0.080 |
Why?
|
| Saliva | 2 | 2021 | 128 | 0.080 |
Why?
|
| Inflammation | 3 | 2023 | 1063 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 382 | 0.070 |
Why?
|
| Ventricular Function, Left | 2 | 2024 | 662 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2013 | 1010 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2010 | 226 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2022 | 883 | 0.070 |
Why?
|
| Kidney | 2 | 2024 | 1135 | 0.070 |
Why?
|
| Los Angeles | 3 | 2013 | 30 | 0.070 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 398 | 0.070 |
Why?
|
| Animals | 5 | 2024 | 28889 | 0.070 |
Why?
|
| Vaccination | 2 | 2022 | 311 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 2042 | 0.070 |
Why?
|
| Mice | 4 | 2024 | 12537 | 0.070 |
Why?
|
| Mass Screening | 2 | 2023 | 710 | 0.060 |
Why?
|
| Residence Characteristics | 2 | 2019 | 213 | 0.060 |
Why?
|
| Triglycerides | 2 | 2021 | 235 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2023 | 854 | 0.060 |
Why?
|
| Cholesterol, HDL | 2 | 2021 | 173 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 2534 | 0.060 |
Why?
|
| Nomograms | 1 | 2025 | 35 | 0.060 |
Why?
|
| Cholesterol | 2 | 2021 | 367 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2012 | 1422 | 0.060 |
Why?
|
| Platelet Count | 1 | 2025 | 91 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 800 | 0.060 |
Why?
|
| Immunoglobulin E | 1 | 2025 | 152 | 0.050 |
Why?
|
| Bumetanide | 1 | 2024 | 4 | 0.050 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2024 | 16 | 0.050 |
Why?
|
| Community Health Workers | 1 | 2025 | 37 | 0.050 |
Why?
|
| Lipocalins | 1 | 2024 | 34 | 0.050 |
Why?
|
| Bundle of His | 1 | 2025 | 53 | 0.050 |
Why?
|
| Manganese | 1 | 2024 | 57 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1670 | 0.050 |
Why?
|
| Blalock-Taussig Procedure | 1 | 2024 | 12 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2025 | 281 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2017 | 397 | 0.050 |
Why?
|
| Guanylate Cyclase | 1 | 2023 | 19 | 0.050 |
Why?
|
| Case Management | 1 | 2023 | 29 | 0.050 |
Why?
|
| Public Health | 1 | 2025 | 155 | 0.050 |
Why?
|
| Rectum | 1 | 2024 | 151 | 0.050 |
Why?
|
| Venous Pressure | 1 | 2023 | 11 | 0.050 |
Why?
|
| Politics | 1 | 2023 | 53 | 0.050 |
Why?
|
| Catastrophization | 1 | 2023 | 10 | 0.050 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2024 | 77 | 0.050 |
Why?
|
| Infant Mortality | 1 | 2023 | 67 | 0.050 |
Why?
|
| Butyrates | 1 | 2023 | 58 | 0.050 |
Why?
|
| Carbohydrates | 1 | 2023 | 49 | 0.050 |
Why?
|
| Dilatation | 1 | 2023 | 48 | 0.050 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2023 | 51 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1230 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 2474 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 2385 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2023 | 151 | 0.050 |
Why?
|
| Ventricular Function, Right | 1 | 2023 | 160 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2023 | 134 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 325 | 0.050 |
Why?
|
| Recurrence | 1 | 2025 | 1211 | 0.050 |
Why?
|
| Shock, Septic | 1 | 2023 | 125 | 0.050 |
Why?
|
| Triage | 1 | 2023 | 132 | 0.040 |
Why?
|
| Bile Ducts | 1 | 2022 | 61 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2023 | 220 | 0.040 |
Why?
|
| Aorta, Thoracic | 1 | 2023 | 170 | 0.040 |
Why?
|
| Vehicle Emissions | 1 | 2021 | 3 | 0.040 |
Why?
|
| Anthropometry | 1 | 2021 | 78 | 0.040 |
Why?
|
| Sputum | 1 | 2021 | 36 | 0.040 |
Why?
|
| Pregnancy in Diabetics | 1 | 2021 | 41 | 0.040 |
Why?
|
| Morbidity | 1 | 2021 | 160 | 0.040 |
Why?
|
| Prescriptions | 1 | 2021 | 26 | 0.040 |
Why?
|
| Travel | 1 | 2021 | 73 | 0.040 |
Why?
|
| Air Microbiology | 1 | 2020 | 5 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 219 | 0.040 |
Why?
|
| Heart Block | 1 | 2020 | 32 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2023 | 340 | 0.040 |
Why?
|
| Knowledge | 1 | 2020 | 29 | 0.040 |
Why?
|
| Social Class | 1 | 2021 | 145 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 2022 | 183 | 0.040 |
Why?
|
| Counseling | 1 | 2022 | 174 | 0.040 |
Why?
|
| DNA, Fungal | 1 | 2020 | 61 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2024 | 460 | 0.040 |
Why?
|
| Fetal Growth Retardation | 1 | 2021 | 72 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 286 | 0.040 |
Why?
|
| Dust | 1 | 2020 | 26 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2020 | 93 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 329 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2022 | 536 | 0.040 |
Why?
|
| Housing | 1 | 2020 | 50 | 0.040 |
Why?
|
| Ventricular Pressure | 1 | 2020 | 48 | 0.040 |
Why?
|
| North America | 1 | 2021 | 199 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 134 | 0.040 |
Why?
|
| Methionine | 1 | 2020 | 68 | 0.040 |
Why?
|
| Fungi | 1 | 2020 | 67 | 0.040 |
Why?
|
| Coronary Angiography | 1 | 2021 | 261 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2022 | 292 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2021 | 117 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 120 | 0.040 |
Why?
|
| Respiratory System | 1 | 2020 | 120 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2020 | 253 | 0.040 |
Why?
|
| Meglumine | 1 | 2019 | 38 | 0.040 |
Why?
|
| Critical Care | 1 | 2023 | 447 | 0.040 |
Why?
|
| Elastic Tissue | 1 | 2019 | 18 | 0.040 |
Why?
|
| Palliative Care | 1 | 2021 | 271 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2022 | 1124 | 0.040 |
Why?
|
| Polysomnography | 1 | 2020 | 155 | 0.040 |
Why?
|
| Placenta | 1 | 2021 | 191 | 0.040 |
Why?
|
| Autopsy | 1 | 2019 | 127 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2020 | 253 | 0.040 |
Why?
|
| Depression | 1 | 2023 | 560 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2020 | 348 | 0.040 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 72 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2019 | 148 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 797 | 0.030 |
Why?
|
| Informed Consent | 1 | 2020 | 281 | 0.030 |
Why?
|
| Computers, Handheld | 1 | 2018 | 33 | 0.030 |
Why?
|
| Poverty Areas | 1 | 2018 | 37 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 816 | 0.030 |
Why?
|
| Cell Phone | 1 | 2018 | 38 | 0.030 |
Why?
|
| Artifacts | 1 | 2019 | 252 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2022 | 705 | 0.030 |
Why?
|
| Patient Selection | 1 | 2021 | 708 | 0.030 |
Why?
|
| Lung | 1 | 2024 | 1380 | 0.030 |
Why?
|
| Social Work | 1 | 2017 | 22 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 468 | 0.030 |
Why?
|
| Dairy Products | 1 | 2016 | 13 | 0.030 |
Why?
|
| Video Recording | 1 | 2018 | 215 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 74 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 1349 | 0.030 |
Why?
|
| Attitude | 1 | 2017 | 137 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 1021 | 0.030 |
Why?
|
| Algorithms | 1 | 2025 | 2015 | 0.030 |
Why?
|
| Patient Preference | 1 | 2017 | 126 | 0.030 |
Why?
|
| Teaching | 1 | 2017 | 154 | 0.030 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 28 | 0.030 |
Why?
|
| China | 1 | 2016 | 264 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2017 | 323 | 0.030 |
Why?
|
| Urban Population | 1 | 2017 | 240 | 0.030 |
Why?
|
| Cecum | 1 | 2015 | 78 | 0.030 |
Why?
|
| Croatia | 1 | 2015 | 1 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1208 | 0.030 |
Why?
|
| Weight Gain | 1 | 2015 | 129 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1816 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1559 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2015 | 134 | 0.030 |
Why?
|
| Contrast Media | 1 | 2019 | 1096 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 404 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 599 | 0.030 |
Why?
|
| Body Fat Distribution | 1 | 2014 | 13 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 1127 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 930 | 0.030 |
Why?
|
| Xanthophylls | 1 | 2013 | 2 | 0.030 |
Why?
|
| Cryptoxanthins | 1 | 2013 | 2 | 0.030 |
Why?
|
| beta Carotene | 1 | 2013 | 4 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2015 | 312 | 0.030 |
Why?
|
| Dietary Proteins | 1 | 2013 | 31 | 0.030 |
Why?
|
| Dietary Carbohydrates | 1 | 2013 | 39 | 0.020 |
Why?
|
| Vitamin E | 1 | 2013 | 34 | 0.020 |
Why?
|
| Micronutrients | 1 | 2013 | 18 | 0.020 |
Why?
|
| Australia | 1 | 2013 | 124 | 0.020 |
Why?
|
| Maintenance Chemotherapy | 1 | 2013 | 91 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2017 | 372 | 0.020 |
Why?
|
| Rituximab | 1 | 2013 | 132 | 0.020 |
Why?
|
| Folic Acid | 1 | 2013 | 63 | 0.020 |
Why?
|
| Sleep | 1 | 2017 | 459 | 0.020 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2012 | 11 | 0.020 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2012 | 11 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 473 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 17 | 0.020 |
Why?
|
| Oleic Acid | 1 | 2012 | 15 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 48 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 311 | 0.020 |
Why?
|
| Mutagens | 1 | 2012 | 29 | 0.020 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2012 | 13 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2014 | 281 | 0.020 |
Why?
|
| Quinoxalines | 1 | 2012 | 51 | 0.020 |
Why?
|
| Physical Exertion | 1 | 2012 | 39 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 220 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 857 | 0.020 |
Why?
|
| Antioxidants | 1 | 2013 | 232 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2012 | 278 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 150 | 0.020 |
Why?
|
| Premenopause | 1 | 2011 | 63 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 175 | 0.020 |
Why?
|
| Lipids | 1 | 2012 | 285 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2011 | 198 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 313 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 579 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 712 | 0.020 |
Why?
|
| Heart Failure | 1 | 2020 | 1422 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1008 | 0.020 |
Why?
|
| Vitamin D | 1 | 2011 | 273 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 3491 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1166 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 933 | 0.020 |
Why?
|